MapLight Therapeutics, Inc. 8-K

What Happened
MapLight Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 via a press release issued and furnished on May 14, 2026. The press release reporting the company’s Q1 2026 results is attached to the Form 8-K as Exhibit 99.1. On the same date the company also updated its corporate presentation for investor meetings; that presentation is available on the company website and is furnished as Exhibit 99.2. The Form 8-K was signed by CEO Christopher A. Kroeger, M.D.

Key Details

• Filing date: May 14, 2026 (Form 8-K filed and exhibits furnished).
• Reporting period: Quarter ended March 31, 2026 (Q1 2026 results announced).
• Exhibits furnished: 99.1 = Press Release (Q1 2026 results); 99.2 = Corporate Presentation (updated).
• Regulation FD disclosure: presentation provided for broad investor dissemination; filing follows Form 8-K General Instruction B.2.

Why It Matters
The 8-K notifies investors that MapLight has released its latest quarterly financial results and refreshed its investor presentation—both of which may contain revenue, expense, cash position, program updates or other material metrics that can affect valuation and investor decisions. Retail investors should review Exhibit 99.1 (the press release) and Exhibit 99.2 (the presentation) on the company’s website or in the SEC filing for the detailed financial and operational figures referenced.